Drug Profile
AIC 6020
Alternative Names: AIC-6020Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator PHD Biosciences
- Class Small molecules
- Mechanism of Action Antioxidants; Haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sickle cell anaemia
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Sickle cell anaemia in USA (unspecified route) (PHD Biosciences website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA
- 12 Aug 2016 Preclinical trials in Sickle cell anaemia in USA (unspecified route)